Author: Leah Davis
-
GLP-1s were meant for chronic disease. How did they become a cosmetic trend?
If solving the obesity crisis was just about dropping pounds, with the help of GLP-1s, we’d have already accomplished that task. But, weight loss is more than a checked box or renewed prescription. It’s a lifestyle change.
-
Erica Terry’s Transformation Through Sustainable Behavior Change
Conversations about weight loss often center on diets, medications, or the number on the scale. But for our very own Erica Terry, Director of Sales, Payer/PBM at Vida Health, the most important lesson was much simpler and far more powerful…
-
Why precision matters in obesity care
Over the past several years, obesity care has entered a new era of clinical sophistication…
-
Telecom Case study
See the outcomes of a large telecom company that executed responsible GLP-1 management and metabolic control through their partnership with Vida.
-
The case for a new standard in metabolic health measurement
For decades, body mass index (BMI) has served as the shorthand for defining obesity and, by extension, metabolic health…
-
The Viewpoint from Vida: where does AI fit into healthcare?
AI in telehealth must be governed by the principle of “do no harm” and must serve, not shape, care. AI improves care by reducing clinical workflow friction and streamlining data among other benefits however, when it comes to healthcare where do we have a responsibility to be sure humans are calling the shots?
-
CapRx Case Study
See the outcomes of a coordinated solution that pairs Vida’s personalized care with Judi® -driven medication management promoting behavior change and appropriate use of GLP-1s.
-
The Employer’s Guide to GLP-1 Coverage Strategy
GLP-1 medications have changed the conversation about metabolic care. It has also created a delicate balancing act between cost and accessibility for employers.
-
The Consultant’s Guide to GLP-1 Coverage Strategy
GLP-1 medications have changed the conversation about metabolic care. It has also created a delicate balancing act between cost and accessibility for employers, and the consultants who guide them.
-
The Viewpoint from Vida: what happens after GLP-1s?
Whether or not someone continues GLP-1 therapy is a clinical decision that should be made in partnership with their healthcare provider. But what are the strategic benefits, and what are the risks?